THERAPY DOSSIER · th-6c54cb5c072e

ucf-101

Drug · ucf-101 is a selective Omi/HtrA2 serine protease inhibitor (research tool); no confident ChEMBL name match returned

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: ucf-101 is a selective Omi/HtrA2 serine protease inhibitor (research tool); no confident ChEMBL name match returned
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26004679 ↗2015Reported benefit

Acute administration of ucf-101 ameliorates the locomotor impairments induced by a traumatic spinal cord injury.

MouseSpinal cord injuryContusionC57BL/6Acute administration beginning after injury

Model: Moderate contusive spinal cord injury

ucf-101 reduced the extent of tissue damage and improved motor function recovery after contusive spinal cord injury, with effects attributed to HtrA2/OMI inhibition, increased XIAP and ERK1/2 activation.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…